Novartis antibody new drug Busizumab injection new indication declared for market in China
楚一帆
发表于 2024-10-12 11:45:08
133
0
0
On October 12th, the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that Novartis' application for the listing of Busizumab injection has been accepted, but the specific indications have not yet been disclosed.
Public data show that brucizumab is a new generation of fundus disease treatment drug targeting to inhibit VEGF, which has previously been approved internationally for the treatment of wet age-related macular degeneration (wAMD, also known as nAMD) and diabetes macular edema (DME). In China, the first listing application for this product was accepted in August last year, and this is the second listing application for this product in China.
Busizumab has been approved for the treatment of nAMD and DME in dozens of countries worldwide, but in China, it has not yet received formal approval from the National Medical Products Administration. But Novartis' public information shows that it has previously been approved for clinical urgent use in designated medical institutions in the Greater Bay Area through the "Hong Kong Macau Medical Device Connect" policy. According to the official website of the China Drug Clinical Trial Registration and Information Disclosure Platform, Novartis has completed at least three Phase 3 clinical trials of buxolizumab in China.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Sanofi: New indications for dabitol have been given priority review by the US FDA
- Novo Nordisk: Positive progress made in reducing the risk of kidney disease with Smegglutide injections
- BeiGene: The first indication approved for tirizizumab in the United States
- Novo Nordisk Smegglutide Injection Approved for Weight Loss Indications in China
- Novo Nordisk Smegglutide Injection Approved for Weight Loss Indications in China
- Novo Nordisk Smegglutide Weight Loss Indications Approved in China, Next Battle is Capacity
- Eli Lilly and Predator Peptide Approved for Long term Weight Management Indications in China
- Dexmedetomidine monoclonal antibody adds new indications for advanced gastric cancer
-
【英偉達の需要が高すぎる?SKハイニックス:黄仁勲がHBM 4チップの6カ月前納入を要求!】SKハイニックスの崔泰源(チェ・テウォン)会長は月曜日、インビダーの黄仁勲(ファン・インフン)CEOが同社の次世代高帯域 ...
- 琳271
- 前天 17:54
- 支持
- 反对
- 回复
- 收藏
-
ファイザーが前立腺がんを治療する革新薬テゼナ& ;reg;(TALZENNA®,一般名:トルエンスルホン酸タラゾールパーリカプセル)は2024年10月29日に国家薬品監督管理局(NMPA)の承認を得て、HRR遺伝子突然変異 ...
- 什么大师特
- 昨天 17:41
- 支持
- 反对
- 回复
- 收藏
-
南方財経は11月5日、中央テレビのニュースによると、現地時間11月5日、米ボーイング社のストライキ労働者が59%の投票結果で新たな賃金協定を受け入れ、7週間にわたるストライキを終えた。ストライキ労働者は11月12 ...
- Dubssgshbsbdhd
- 昨天 16:27
- 支持
- 反对
- 回复
- 收藏
-
【マスクはテスラが携帯電話を作ることに応えた:作れるが作らないアップルとグーグルが悪さをしない限り】現地時間11月5日、有名ポッドキャストのジョローガン氏のインタビューに応じ、「携帯電話を作るのは私たち ...
- 波大老师
- 昨天 14:41
- 支持
- 反对
- 回复
- 收藏